PATENT CLAIM ANALYSIS

Application Number: 16302722
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-07
Patent Classification: ["514", "323000"]

Abstract:
The present disclosure describes compositions and methods for treating at least one negative symptom in a human subject who does not have a clinical diagnosis of schizophrenia. The compositions and methods employ a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof.

Claim (Index 19):
The method of  claim 11 , wherein Compound I is administered to the subject for a first treatment period of at least 2 weeks, at least 4 weeks, at least 6 weeks, at least 8 weeks, at least 10 weeks or at least 12 weeks and, if the subject experiences improvement in at least one negative symptom during the first treatment period, then administration of the therapeutically effective amount of Compound I is continued for a second treatment period of at least 12 weeks, at least 24 weeks, at least 48 weeks or until the subject is determined to be in remission from the negative symptoms.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 98.0
- Lexical Diversity: 1.31111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15211638', '15853151', '15484960', '13213960', '14635905']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7082832548068844
- 35 USC 102 Novelty (BERT): 0.4926023059968666
- Combined Prediction Score: 0.6867151599258826
- Mean Citation Score: 159.67431399999995
- Max Citation Score: 170.6875
- Similarity Product: 110.49093352630732

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test